Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Analysts

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating) have received an average recommendation of “Buy” from the nine research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $44.00.

XENE has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, March 2nd. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, March 2nd. TheStreet upgraded shares of Xenon Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Monday, March 14th. Finally, StockNews.com initiated coverage on shares of Xenon Pharmaceuticals in a research report on Thursday, March 31st. They set a “sell” rating on the stock.

In other Xenon Pharmaceuticals news, EVP Sherrington Robin sold 21,710 shares of the stock in a transaction dated Friday, March 4th. The shares were sold at an average price of $30.50, for a total transaction of $662,155.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP James R. Empfield sold 32,853 shares of the stock in a transaction dated Monday, March 7th. The shares were sold at an average price of $30.54, for a total transaction of $1,003,330.62. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 94,974 shares of company stock valued at $2,899,047. 7.48% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in XENE. Suvretta Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 95.1% during the third quarter. Suvretta Capital Management LLC now owns 1,158,961 shares of the biopharmaceutical company’s stock valued at $17,709,000 after acquiring an additional 564,850 shares in the last quarter. Altium Capital Management LP increased its holdings in shares of Xenon Pharmaceuticals by 39.4% during the third quarter. Altium Capital Management LP now owns 216,000 shares of the biopharmaceutical company’s stock valued at $3,300,000 after acquiring an additional 61,000 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in shares of Xenon Pharmaceuticals by 24.3% during the third quarter. Schonfeld Strategic Advisors LLC now owns 120,121 shares of the biopharmaceutical company’s stock valued at $1,836,000 after acquiring an additional 23,521 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Xenon Pharmaceuticals by 19.5% during the third quarter. Point72 Asset Management L.P. now owns 1,077,800 shares of the biopharmaceutical company’s stock valued at $16,469,000 after acquiring an additional 175,500 shares in the last quarter. Finally, Brown Advisory Inc. acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at about $403,000. 69.15% of the stock is owned by institutional investors and hedge funds.

XENE traded down $0.29 during trading hours on Friday, hitting $32.43. The company’s stock had a trading volume of 871 shares, compared to its average volume of 449,503. The business’s 50-day moving average price is $31.52 and its 200-day moving average price is $29.88. Xenon Pharmaceuticals has a 12 month low of $14.65 and a 12 month high of $36.42. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -17.59 and a beta of 1.79.

Xenon Pharmaceuticals (NASDAQ:XENEGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.10). Xenon Pharmaceuticals had a negative return on equity of 24.14% and a negative net margin of 425.88%. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $4.20 million. During the same quarter in the prior year, the firm posted ($0.34) EPS. As a group, equities analysts predict that Xenon Pharmaceuticals will post -2.17 earnings per share for the current year.

Xenon Pharmaceuticals Company Profile (Get Rating)

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

Further Reading

Analyst Recommendations for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.